Corcept Therapeutics Incorporated (LON: 0I3Q)
London
· Delayed Price · Currency is GBP · Price in USD
58.22
+1.97 (3.50%)
Jan 22, 2025, 7:04 PM BST
Corcept Therapeutics Employees
Corcept Therapeutics had 352 employees as of December 30, 2023. The number of employees increased by 53 or 17.73% compared to the previous year.
Employees
352
Change (1Y)
53
Growth (1Y)
17.73%
Revenue / Employee
1.33M GBP
Profits / Employee
297.78K GBP
Market Cap
5.02B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Corcept Therapeutics News
- 23 days ago - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
- 5 weeks ago - Corcept Therapeutics Inc (CORT) Announces Promising Phase 3 Study Results for Relacorilant - GuruFocus
- 5 weeks ago - Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Business Wire
- 5 weeks ago - Corcept Therapeutics Inc (CORT) Announces Positive Results from CATALYST Study - GuruFocus
- 5 weeks ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Benzinga
- 5 weeks ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Business Wire
- 6 weeks ago - Corcept Therapeutics' ALS drug fails in mid-stage trial - Reuters
- 6 weeks ago - Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Business Wire